Plants
|
|
[95] |
the amount of material depends on seasonality of plants
the quality of NPs depends on the growth, harvesting conditions and geographical distribution of plants
|
[130] |
|
[100] |
|
[96] |
|
[98] |
specific process conditions such as temperature, pressure, reaction time, chemical reagents additions
variation in NPs quality due to irregular shape and size
|
[59] |
small particle size and zeta potential indicate good stability
enhanced biodistribution, efficacy and safety for NPs compared to raw extracts
|
[130] |
|
[97] |
|
[100] |
possible neurotoxicity, tissue toxicity
only a few are approved by EMA and FDA, thus needing further analyses.
|
[131] |
|
[99] |
|
[100] |
Microorganisms
|
|
[132] |
tedious purification steps
poor/lack of understanding of the competitive antimicrobial mechanisms
challenges in translating the production of NPs to industrial scale
potentially diminished yield caused by the growth rate of bacteria, enzymatic activity, biochemical pathways and purification processes.
|
[133] |
|
[134] |
ease of cultivation and adjustment of size, shape and morphology of NPs
effective penetration through matrix biofilm produced by pathogenic agents, NPs play the role of a “Trojan horse” for bacterial cells.
|
[134] |
Algae
|
|
[135] |
limited applicability, low biocompatibility and, in some cases, elevated toxicity
no clear reaction mechanism during NPs formation
|
[136] |
biocompatibility
cost-effectiveness
versatility
|
[137] |
|
[138] |
irregular shapes and sizes depending on solvents, vehicle, pH, exposure time and age of algal extract.
|
[59] |